Oncolines – Case Studies

Oncolines is a daughter company of Symeres. Oncolines B.V. was founded in 2021 as a spin-off company of Netherlands Translational Research Center B.V. (NTRC), a biotech company established in Oss (The Netherlands) in 2011 by former employees of Organon/MSD.

Oncolines is named after its large cancer cell line panel (the Oncolines® panel) and its cell line proliferation assay and bioinformatics services.

Reproducible Results, Short Timelines, Swift Communications

We provide high quality results with a short delivery time. Direct contact between our staff and sponsors results in efficient scientific and technical support. We provide cost-free consultation on next steps in research if desired by the sponsor.

Case study – Target validation by combining Oncolines® profiling and gene dependency screens

Case study – Target validation by combining Oncolines® profiling and gene dependency screens

Case study – Target validation by combining Oncolines® profiling and gene dependency screens

janneke2024-08-26T10:01:05+02:00

Case study – Protein expression analysis identifies predictive drug-response markers for the MEK inhibitor trametinib

Case study – Protein expression analysis identifies predictive drug-response markers for the MEK inhibitor trametinib

Case study – Protein expression analysis identifies predictive drug-response markers for the MEK inhibitor trametinib

Oncolines®2024-03-18T16:59:40+01:00

Oncolines Casestudy Target Identification Via Oncolines® Profiling And ResidenceTimer™

Case study – Target identification via Oncolines® profiling and ResidenceTimer™

Case study – Target identification via Oncolines® profiling and ResidenceTimer™

Case study – Target identification via Oncolines® profiling and ResidenceTimer™

Oncolines®2024-08-26T10:54:25+02:00

Case study – Gene expression profiling to understand and combat drug resistance

Case study – Gene expression profiling to understand and combat drug resistance

Case study – Gene expression profiling to understand and combat drug resistance

janneke2023-05-29T15:56:23+02:00

Case study – Combination matrix to determine Bliss independence synergy scores

Case study – Combination matrix to determine Bliss independence synergy scores

Case study – Combination matrix to determine Bliss independence synergy scores

Oncolines®2024-07-04T09:50:26+02:00

Case study – 3D spheroid drug sensitivity

Case study – 3D spheroid drug sensitivity

Case study – 3D spheroid drug sensitivity

yvonne2024-07-03T11:49:07+02:00

Case study – Pharmacological models to assess the role of tryptophan-metabolizing enzymes in cancer

Case study – Pharmacological models to assess the role of tryptophan-metabolizing enzymes in cancer

Case study – Pharmacological models to assess the role of tryptophan-metabolizing enzymes in cancer

Oncolines®2023-05-29T15:58:13+02:00

Case study – Synergistic interaction of olaparib and cisplatin

Case study – Synergistic interaction of olaparib and cisplatin

Case study – Synergistic interaction of olaparib and cisplatin

Oncolines®2023-05-29T15:59:34+02:00

Case study – TTK patient stratification marker

Case study – TTK patient stratification marker

Case study – TTK patient stratification marker

Oncolines®2023-05-29T16:00:20+02:00

Case study – MEK inhibitor

Case study – MEK inhibitor

Case study – MEK inhibitor

Oncolines®2023-05-29T16:01:07+02:00